Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omega-3 claims petition

This article was originally published in The Tan Sheet

Executive Summary

FDA has filed health claim petition "for conventional foods and dietary supplements relating consumption of omega-3 fatty acids...to reduced risk of coronary heart disease," agency states in Sept. 3 letter to Washington, D.C. law firm Emord & Associates. Emord submitted petition June 23 on behalf of Wellness Lifestyles, Inc., and Life Extension Foundation Buyers Club (1"The Tan Sheet" June 30, 2003, p. 11). Petition is posted on FDA 2website, with open comment period until Nov. 2. Agency will notify petitioners of final decision by April 15, 2004...

You may also be interested in...



Omega-3/Heart Disease Amended Health Claim Without Disclaimer Proposed

FDA should amend the approved health claim linking omega-3 fatty acids to a reduced risk of coronary heart disease by removing the disclaimer and extending the claim to foods, supplement industry members maintain in a June 23 petition

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Approved Nearly 75 Years Ago, Bufferin NDA On Withdrawal Notice Due To Registration Lapse

Attention must be paid when withdrawal is for NDA approved in 1948 for brand synonymous with nonprescription pain relief, Bufferin. Even when FDA’s decision amounts to NDA database recordkeeping, withdrawal of application demands notice in US OTC space.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS095905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel